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and management plans after expert review in North
American studies[3–5] than in UK series[1] likely reflects
greater variation in practice standards in the USA.
Review work should ideally occur within the context of
a multidisciplinary team (MDT) meeting. Such work is
time-consuming and requires the attendance of key
radiologists, pathologists, surgeons, physicians and
paramedical staﬀ, as well as the support of administra-
tors and clerical staﬀ. Notes, films and slides must all be
available and in this forum clinical and pathological
information is often brought to light which resolves
problems, downgrades the clinical impact of radiological
uncertainty or else discussion helps to form management
or investigation plans to respond to this. There is little
reported research on the value of such meetings but such
as it is the data are clear. Clinicians place high value on
time spent within such meetings and they are time-
eﬀective for radiologists[6,7].
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The imaging of malignant disease involves tumour
diagnosis, staging, measurement of response and identi-
fication of complications. Increasingly, oncologic radi-
ologists are expected to provide objective assessment of
change in masses, on serial studies, in order to validate
response or resistance to new chemotherapeutic agents.
In some cancer centres follow-up examinations make up
over 75% of computed tomography (CT) activity.
Objective assessment on CT depends on a somewhat
simplistic assumption that those masses that increase in
size define disease progression, whereas reduction in
tumour size indicates a favourable therapeutic impact.
The 1979 WHO Handbook and the 1981 paper by Miller
et al.[1] identified criteria for bi-dimensional measure-
ments of tumour masses and established the classifica-
tion of Complete Response (CR), Partial Response
(PR), Stable Disease (SD) and Progressive Disease
(PD). It has became apparent, however, during the
application of these criteria that assessments based on
bi-dimensional measurements of one or two marker
lesions could result in misleading conclusions, particu-
larly in respect of progressive disease where increasing
size of a single lesion might be at variance with favour-
able change elsewhere. This could lead to an incorrect
conclusion that therapy was ineﬀective. It has also
become clear that methods for evaluating change in the
size of measurable lesions have not always been univer-
sally applied and diﬀerent observers and even centres
could employ diﬀerent regimes. Husband, Gwyther and
Rankin highlighted these features in 1999[2] when they
described the problems of bi-dimensional measurements
of 3-dimensional masses, as well as the diﬃculties posed
by tumour necrosis and calcification.
In June 1999 a revised version of WHO criteria under
the heading ‘Response Evaluation Criteria in Solid
Tumours (RECIST criteria)’[3] was published, based on
the assessment of up to 10 target lesions, the sum of
whose longest diameters define the baseline measure-
ment. The stimulus for this finite objective measurement
emanates from the licensing authorities, whose require-
ments define phase II drug assessment protocols for the
pharmaceutical industry. RECIST criteria require the
identification up to 10 solid, well-marginated nodules
and their repeated identification and assessment of
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change on serial CT or MRI examinations. The uni-
dimensional measurement of 10 target lesions on
sequential examinations is laborious and fraught with
potential inaccuracy. The application of these criteria
within a busy cancer imaging unit is at best tedious and
expensive and for some tumours impractical. Outside
well-resourced research units, generously staﬀed with
expert observers, these criteria appear to have achieved
little practical relevance.
Neither the original WHO criteria nor RECIST take
into account changes in physical characteristics of
the tumour such as cystic degeneration or calcifica-
tion. Serial measurements of the diameter of an
involved para-aortic lymph node in metastatic non-
seminomatous testicular tumour may well increase
during eﬀective response to chemotherapy. This is com-
monly due to a degree of cystic degeneration within the
mass. This phenomenon is well documented[4] and in this
situation application of RECIST criteria alone may lead
to incorrect conclusions and for individual cases may be
dangerous. Other metastases, e.g. in the liver, may also
undergo necrosis and sarcomas may also increase in
size when necrosis occurs during eﬀective therapy. The
occasional development of tumour calcification may
have varying implication for the assessment of response
but is not considered in these protocols.
Recent discussion[5] has highlighted potential weak-
nesses in RECIST criteria, particularly in relation to the
inability to determine any functional change resulting
from eﬀective drug activity. Tumour neo-angiogenesis
and cellular metabolic changes require assessment by
new dynamic forms of functional imaging such as
18FDG-PET or 31P-magnetic resonance spectroscopy
(MRS). In the vast majority of cancer cases, however,
assessment of response depends on morphological
measurement of appropriate target lesions on serial CT
studies.
Problems of reproducibility are encountered when, on
the basis of Phase II trials subsequent phase III studies
involve several centres and multiple observers.
Gwyther[6,7] has reported the impact of independent
radiological review of image data sets in studies of
Gemcitabine and Topotecan and in both reports showed
that response rates were significantly reduced when
independently reviewed by an expert panel.
The mechanics of these reviews still rely on applica-
tion of WHO criteria of bi-dimensional measurement,
but this task becomes most diﬃcult when the assessment
involves metastatic ovarian cancer. It might be argued
that in this particular disease the application of RECIST
criteria is so fraught with potential inaccuracy that
meaningful objective measurements and conclusions are
scientifically impossible, whether performed by single
observers or review panel. In response to the promulga-
tion of these new guidelines the Gynecologic Cancer
Intergroup have published a recommendation that
for the definition of objective disease progression,
after first-line therapy, the doubling of CA 125 from
the upper limit of normal (or doubling from the
post-treatment nadir) predicts disease progression[8].
Ovarian cancer is a disease which spreads trans-
coelomically, and is characterized by the development of
abdominal ascites and by widespread peritoneal plaques.
Pleural and pericardial eﬀusions together with cystic
lesions are considered by RECIST to be non-measurable
and these patients are excluded from study populations
unless measurable lesions are present. By excluding these
patients and including unreliable data based on
measurements of ill-defined peritoneal and serosal
plaques, the scientific basis for the assessment of thera-
peutic response must be flawed at the very outset. At the
very least the exclusion of a significant percentage of
patients because of non-measurable disease skews the
study population. Technical improvements in CT with
the development of spiral technology, combined with
changes in technique and the more widespread use of
intravenous contrast enhancement, mean that a small
volume plaque as thin as 1–2 mm can be demonstrated
and analysed sequentially by an experienced observer
but reproducible, accurate measurement is seldom feas-
ible. Whilst discrete tumour nodules may be available in
many cases for serial objective measurement (Fig. 1) the
identification of disease reactivation or progression can
be achieved by recognition of more subtle features such
as increasing thickening of wafer-thin enhancing plaques
of disease applied to the serosa of the bowel (Fig. 2).
It is argued, therefore, that for studies involving phase
II trials in ovarian cancer a more accurate and meaning-
ful method of evaluating therapeutic impact could be
aﬀorded by a subjective review of the whole imaging
data set performed by an external panel made up of
experienced radiologists.
During the observation and attempted measurement
of response on serial CT in many cases of ovarian
cancer, and becoming increasingly frustrated in so
doing, the observation of tumour calcification in associ-
ation with metastatic ovarian cancer became increas-
ingly obvious. This well-recognized entity has not,
hitherto, been subjected to any detailed analysis and in
particular its relationship to treatment is unclear. A
retrospective study has, therefore, been undertaken
examining the temporal relationships of clinical and
Figure 1
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radiological features, together with tumour markers in
122 patients who presented with or developed calcifica-
tion within metastatic ovarian cancer. Changes in soft
tissue lesion size and the development of calcification
have been correlated with histopathology and outcome.
The study group was compared with a control group of
1577 patients who had a CT scan performed at least
once during follow-up. A positive relationship between
calcification and tumour sub-type was identified with
serous tumours, which represented 60% of the calcified
group, against 30% in the control. Patients with calcifi-
cation were generally higher stage than the control
group but lower grade. They also had a poorer survival
rate.
There did not seem to be any relationship between the
development of calcification and chemotherapy and
thus it is unusable as a marker of response. Reliable
assessment of metastatic ovarian cancer still remains
extremely diﬃcult and it is contended that for this
disease trial data should be subjected to external panel
review.
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Introduction
Normal cells have three basic outcomes: diﬀerentiation,
division and death. Cancer cells usually have reduced
diﬀerentiation, increased division and mechanisms to
avoid programmed cell death, apoptosis. These proper-
ties can be used to monitor cancer by nuclear medicine
imaging.
Differentiation
Thyroid cancer cells show a reduced ability to take up
radio-iodine compared with normal cells. Thus, all
normal thyroid tissue has to be ablated surgically and
with radio-iodine in order that the papillary or follicular
thyroid cancers show uptake on radioiodine images and
for thyroglobulin, Tg, to be a useful serum marker.
Monitoring of thyroid cancer used to be done with a
tracer amount of radioiodine 131I. It was found that
administration of amounts greater than 185 MBq, 5 mCi
may cause stunning, reducing the of eﬀectiveness of the
large dose of 131I given for therapy, (5–6 GBq, 150 mCi).
However, 185 MBq (or less) 131I gives a poor count rate
signal, so that weakly iodine-avid malignant disease may
not be detected. If the Tg is raised, some authorities are
giving 131I therapy in the absence of proof of iodine
uptake. Some 50% of such patients show no uptake
Figure 2
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